Sp139
POSITIONING ADVANCED IBD THERAPIES
Date
May 18, 2024
Presenter
University of Chicago Division of the Biological Sciences
Tracks
Related Products
ENVIRONMENTAL AND DIETARY FACTORS IN INFLAMMATORY BOWEL DISEASE: A POPULATION-BASED CASE-CONTROL STUDY FROM THE GLOBAL INFLAMMATORY BOWEL DISEASE VISUALIZATION OF EPIDEMIOLOGY STUDIES IN THE 21ST CENTURY (GIVES-21) CONSORTIUM
OBJECTIVE:The rapid emergence of IBD in newly industrialized regions supports the importance of environmental risk factors in disease etiology…
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
